As a novel ADC drug coupled with a TOP1 inhibitor, T-DXd is indicated for the treatment of adult patients with unresectable or metastatic HER2-low breast cancer who have received prior anti-HER2 therapies (22). Here, TOP1 is linked to breast cancer.